# SymbioCellTech **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** Type 1 diabetes, cell therapy, Neo-Islets, mesenchymal stem cells, islet transplantation, regenerative medicine **Stage:** Preclinical → IND-track; ADA Innovation Challenge Award 2024 **Location:** Salt Lake City, UT **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/symbiocelltech-neo-islets-diabetes-2026/1600/1100 **Pull:** *3D islet–MSC clusters that aim to restore insulin without lifetime immunosuppression — if the immune isolation holds in humans.* **Relates:** cites [Official Website: SymbioCellTech](symbiocelltech-official-website.md) ## Summary SymbioCellTech is a Salt Lake City biotechnology company developing Neo-Islets — three-dimensional clusters of culture-expanded insulin-expressing pancreatic cells co-packaged with mesenchymal stem cells (MSCs). The thesis is local immune isolation: MSCs within each cluster shield islet cells from autoimmune and allo-immune attack, eliminating the need for systemic anti-rejection drugs that accompany conventional islet transplantation. The company won the American Diabetes Association Innovation Challenge Award in 2024. Per its official website, it has reported positive preclinical results and ongoing canine studies, with an outpatient intraperitoneal administration route targeting omental engraftment. Founding science traces to clinical academic investigators at the University of Utah and University of Hamburg. ## Impact Type 1 diabetes affects roughly 16 million people worldwide who depend on daily insulin and glucose monitoring. Even rigorous therapy carries long-term complication risk — multi-organ failure, vascular disease, blindness, and reduced life expectancy. Islet transplantation can restore glucose control but typically requires lifelong immunosuppression with serious infection, cancer, and kidney risks, and donor scarcity limits scale (conventional protocols may require multiple pancreas donors per patient). If Neo-Islets achieve durable euglycemia without systemic immunosuppression at manufacturable scale (~80 doses per donor pancreas, per company claims), the impact would be a functional cure rather than incremental improvement — restoring portal insulin delivery physiology instead of subcutaneous injection. Type 2 diabetes adaptation is also described as underway. ## What They Are Building SymbioCellTech's patented Neo-Islet platform addresses four stated technical obstacles: 1. **Immune attack** — MSC-mediated shielding against both autoimmune beta-cell destruction and allo-immune rejection, avoiding encapsulation devices prone to foreign-body reactions. 2. **Donor scarcity** — culture expansion and cluster geometry to multiply doses from a single pancreas donor. 3. **Vascularization** — MSC pro-angiogenic support for neo-vascularization of engrafted clusters. 4. **Physiologic insulin delivery** — omental engraftment with portal-system insulin release mimicking native pancreatic routing. Administration is described as a simple outpatient intraperitoneal procedure with lifetime treatment intent. Preclinical work includes rodent models and an FDA-guided canine pilot (INAD) with reported insulin reduction and glucose improvements sustained over 15+ months in some animals. ## What They Need Now Likely needs include cell-therapy manufacturing scientists, immunology and transplant biology advisors, GMP process-development engineers, regulatory affairs specialists for IND-enabling studies and CBER interactions, clinical-trial operations staff, and capital for human proof-of-concept trials. The key unproven claim — durable MSC-mediated immune privilege at clinical scale — demands rigorous controlled human data. ## Who Could Help Useful helpers include islet-transplant clinical investigators, diabetes KOLs familiar with immunosuppression-sparing approaches, FDA cell-therapy regulatory consultants, CRO partners for Phase 1/2 trial design, pancreas procurement and islet-isolation networks, and Utah life-sciences ecosystem connectors (Altitude Lab and related networks). ## Utah Context SymbioCellTech is headquartered in Salt Lake City (615 Arapeen Drive area) and was established by University of Utah and University of Hamburg investigators. It sits in Utah's regenerative-medicine and cell-therapy cluster alongside companies like [Recursion Pharmaceuticals](recursion-pharmaceuticals.md) and [Culmination Bio](culmination-bio.md), though SymbioCellTech is earlier-stage and therapy-focused rather than data-platform or discovery-at-scale. ## Evidence - [Official Website: SymbioCellTech](symbiocelltech-official-website.md) - [PLOS ONE: Neo-Islets donor-pool expansion (2023)](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0290460) - [StartUp Health profile](https://www.startuphealth.com/startup-health-blog/symbiocelltechs-stem-cell-enabled-therapy-could-offer-a-functional-cure-for-type-1-diabetes-without-requiring-anti-rejection-drugs) ## See Also - [Recursion Pharmaceuticals](recursion-pharmaceuticals.md) — Utah neighbor in computational drug discovery at very different stage and modality - [Culmination Bio](culmination-bio.md) — Utah clinical-data platform that could eventually inform diabetes cohort research ## Open Questions - IND submission and current FDA regulatory status are unclear; the company website still references Phase I human trials "aiming to begin in 2023," which appears stale. - MSC-mediated local immune privilege for transplanted islets is biologically plausible in some contexts but not yet demonstrated as durable protection in controlled human trials. - Islet transplantation has a long history of promising preclinical results that fail to replicate clinically — independent replication of Neo-Islet efficacy and safety is essential. - Manufacturing consistency, long-term cluster viability, and whether immune protection wanes over years remain open. - Ownership, funding level, and team size are not established on this page; third-party sources suggest private funding but details vary.